What happened with CRIS today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
Curis focuses on emavusertib, an experimental cancer drug still in early-stage clinical development. Its main studies test the drug with ibrutinib for primary central nervous system lymphoma that has returned or resisted treatment, and with zanubrutinib for chronic lymphocytic leukemia. The business depends heavily on this one drug candidate, whose effectiveness in humans remains unproven.
Curis currently has no revenue and relies on funding sources such as equity offerings to continue development. It previously received royalties from Genentech’s sales of Erivedge, but sold that business in November 2025 and no longer receives revenue under the agreement. Future drug revenue requires successful trials, marketing approval and commercialization, with private insurers and government payors providing coverage and reimbursement. Emavusertib has not received marketing approval and cannot yet be sold commercially.
Curis licenses emavusertib-related rights from Aurigene outside India and Russia, and owes Aurigene payments tied to milestones and future sales. It has no manufacturing capabilities and plans to pursue emavusertib with a collaborator. Continuing the program therefore depends on additional financing, outside trial and manufacturing providers, and securing a suitable development partner.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
Curis’s prospects hinge on financing and clinical results for emavusertib, licensed from Aurigene, rather than the Erivedge royalties it sold in November 2025.
Rigel Pharmaceuticals Inc. (New) competes with Curis in blood-cancer drug development: its R289 blocks IRAK1/4, while Curis’s emavusertib targets IRAK4. Rigel already sells medicines for blood disorders and cancer, but R289’s clinical progress is the news most relevant to Curis.
BeOne Medicines sells zanubrutinib, the drug Curis combines with emavusertib in its chronic lymphocytic leukemia (CLL) trial, but also develops competing CLL and primary central nervous system lymphoma (PCNSL) regimens. Watch its combination-treatment results in those diseases, rather than treating zanubrutinib sales alone as evidence for Curis’s regimen.
Nurix Therapeutics, Inc. develops drugs that remove the BTK protein—BTK degraders—for CLL, potentially competing with Curis’s emavusertib-plus-zanubrutinib regimen. Nurix has no approved products and earns revenue from research collaborations and licenses; its CLL clinical progress, not product sales, is what matters for this comparison.
AstraZeneca competes with Curis on two fronts: it develops the IRAK4 inhibitor AZD2962 and sells acalabrutinib-based CLL treatment. Results for AZD2962 and uptake of acalabrutinib combined with venetoclax are the relevant signals for emavusertib and Curis’s CLL combination strategy.
AbbVie’s ibrutinib-based treatments compete in Curis’s CLL and PCNSL indications, yet ibrutinib is also the drug Curis pairs with emavusertib in relapsed or refractory PCNSL. Results from ibrutinib combinations in those patients are therefore more relevant to Curis than AbbVie’s overall medicine sales.
Eli Lilly’s pirtobrutinib-based CLL regimens compete with the emavusertib-plus-zanubrutinib strategy Curis is testing. For Curis holders, the useful news from this medicine developer and seller is clinical progress in those CLL regimens, rather than company-wide sales.
Johnson & Johnson’s ibrutinib-based CLL regimens compete with Curis’s emavusertib-plus-zanubrutinib program; it sells prescription medicines through retailers, wholesalers and healthcare providers. Watch progress and use of ibrutinib combined with venetoclax in frontline CLL, the treatment setting Curis identifies as a competitive area.
Gilead Sciences is pursuing axicabtagene ciloleucel as a competing PCNSL treatment to Curis’s emavusertib-plus-ibrutinib regimen. Although Gilead develops and sells medicines across several diseases, results for this approach in relapsed or refractory PCNSL are the news most directly relevant to Curis.
Curis Inc earningsThis company
Curis’s report will show whether progress in emavusertib trials is keeping pace with the cash the company spends, and whether it can keep funding its lead drug’s development.
Read emavusertib trial progress alongside cash used in operations. Trials moving forward as cash use falls would suggest Curis is extending its funding runway without slowing its lead program; delays alongside continued heavy cash use would suggest funding could run short before the company has meaningful clinical evidence, increasing pressure to raise money or cut development.
